Internalization and recycling of delta-opioid receptor are dependent on a phosphorylation-dephosphorylation mechanism

Author(s): Hasbi A, Allouche S, Sichel F, Stanasila L, Massotte D, et al.

Abstract

Internalization, recycling, and resensitization of the human delta-opioid receptor (hDOR) were studied in the neuroblastoma cell line SK-N-BE, endogenously expressing this receptor. Conventional and confocal fluorescence microscopy observations, corroborated by Scatchard analysis, indicated that after a 100 nM Eto treatment, 60 to 70% of hDOR were rapidly internalized (t(1/2) < 15 min). This agonist-triggered internalization was reversible for a treatment not exceeding 1 h and became irreversible for prolonged treatment (4 h), leading probably to the degradation and/or down-regulation of the receptor. The rapid internalization of hDOR was totally blocked in the presence of heparin, known as an inhibitor of G protein-coupled receptor kinases (Benovic et al., 1989), a result indicating that phosphorylation by these kinases is a critical step in desensitization (Hasbi et al, 1998) and internalization of hDOR (present study) in SK-N-BE cell line. Blockade of internalization by agents not interferring with phosphorylation, as hypertonic sucrose or concanavalin A, also blocked the resensitization (receptor functional recovering) process. Furthermore, blockade of dephosphorylation of the internalized hDOR by okadaic acid totally suppressed its recycling to the plasma membrane and its subsequent resensitization. These results indicate that regulatory events leading to desensitization, internalization, and recycling in a functional state of hDOR involve phosphorylation by a G protein-coupled receptor kinase, internalization via clathrin-coated vesicles, and dephosphorylation by acid phosphatases.

Similar Articles

Enhanced morphine analgesia in mice lacking beta-arrestin 2

Author(s): Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, et al.

Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence

Author(s): Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG, et al.

Ligand-directed signalling within the opioid receptor family

Author(s): Pradhan AA, Smith ML, Kieffer BL, Evans CJ

μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization

Author(s): McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, et al.

Morphine-like opiates selectively antagonize receptor-arrestin interactions

Author(s): Molinari P, Vezzi V, Sbraccia M, Grò C, Riitano D, et al.

Pharmacological characterization of AR-M1000390 at human delta opioid receptors

Author(s): Marie N, Landemore G, Debout C, Jauzac P, Allouche S

SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors

Author(s): Polastron J, Mur M, Mazarguil H, Puget A, Meunier JC, et al.

ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands

Author(s): Aguila B, Coulbault L, Davis A, Marie N, Hasbi A, et al.

Molecular control of δ-opioid receptor signalling

Author(s): Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, et al.

Development and validation of a genetic algorithm for flexible docking

Author(s): Jones G, Willett P, Glen RC, Leach AR, Taylor R, et al.

Agonist-selective mechanisms of GPCR desensitization

Author(s): Kelly E, Bailey CP, Henderson G

Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone

Author(s): Quillinan N, Lau EK, Virk M, von Zastrow M, Williams JT

Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes

Author(s): Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, et al.